全文获取类型
收费全文 | 17808篇 |
免费 | 1247篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 990篇 |
妇产科学 | 338篇 |
基础医学 | 1770篇 |
口腔科学 | 21篇 |
临床医学 | 1875篇 |
内科学 | 6153篇 |
皮肤病学 | 257篇 |
神经病学 | 1605篇 |
特种医学 | 90篇 |
外科学 | 1862篇 |
综合类 | 309篇 |
一般理论 | 1篇 |
预防医学 | 1342篇 |
眼科学 | 732篇 |
药学 | 681篇 |
中国医学 | 25篇 |
肿瘤学 | 1016篇 |
出版年
2024年 | 25篇 |
2023年 | 158篇 |
2022年 | 106篇 |
2021年 | 184篇 |
2020年 | 156篇 |
2019年 | 81篇 |
2018年 | 324篇 |
2017年 | 327篇 |
2016年 | 372篇 |
2015年 | 400篇 |
2014年 | 313篇 |
2013年 | 555篇 |
2012年 | 1446篇 |
2011年 | 1581篇 |
2010年 | 533篇 |
2009年 | 542篇 |
2008年 | 1616篇 |
2007年 | 1581篇 |
2006年 | 1358篇 |
2005年 | 1460篇 |
2004年 | 1509篇 |
2003年 | 1607篇 |
2002年 | 1178篇 |
2001年 | 897篇 |
2000年 | 184篇 |
1999年 | 99篇 |
1998年 | 119篇 |
1997年 | 90篇 |
1996年 | 51篇 |
1995年 | 34篇 |
1994年 | 38篇 |
1993年 | 24篇 |
1992年 | 16篇 |
1991年 | 14篇 |
1990年 | 24篇 |
1989年 | 14篇 |
1988年 | 19篇 |
1987年 | 13篇 |
1986年 | 9篇 |
1985年 | 4篇 |
1984年 | 12篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 11篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1970年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Ekouevi DK Rouet F Becquet R Inwoley A Viho I Tonwe-Gold B Bequet L Dabis F Leroy V;ANRS / Ditrame Plus Study Group 《Journal of acquired immune deficiency syndromes (1999)》2004,36(2):755-757
The aim of this study performed in Abidjan, C?te d'Ivoire, was to describe the distribution of CD4+ T-cell lymphocytes (CD4) in HIV-1-infected (HIV+) pregnant women diagnosed during prenatal voluntary counseling and testing and to assess whether HIV-related immunodeficiency influenced the acceptance of an antiretroviral (ARV) package (zidovudine beginning at 36 weeks of amenorrhea plus intrapartum nevirapine) to prevent mother-to-child transmission. Between April and June 2002, a CD4 count was systematically performed in all HIV+ women (n=221) in 5 antenatal clinics carrying out voluntary counseling and testing. No difference in CD4 count was found in HIV+ women who did not return for their test result (n=50) and those who were informed of their positive serostatus (n=171) (median CD4 count: 389/mm3 vs. 420/mm3; P=0.19). We also found a lack of difference in CD4 count in those who accepted ARV (n=72) and those who did not but knew their HIV status (n=99) (median CD4 count: 405/mm3 vs. 425/mm3; P=0.47). The overall uptake of the intervention (31.9%) appeared to be independent of the maternal immune status. 相似文献
32.
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure 总被引:9,自引:0,他引:9
Yancy CW Fowler MB Colucci WS Gilbert EM Bristow MR Cohn JN Lukas MA Young ST Packer M;U.S. Carvedilol Heart Failure Study Group 《The New England journal of medicine》2001,344(18):1358-1365
BACKGROUND: The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure. METHODS: In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients. RESULTS: As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent in nonblack patients. Carvedilol reduced the risk of worsening heart failure (heart failure leading to death, hospitalization, or a sustained increase in medication) by 54 percent in black patients and by 51 percent in nonblack patients. The ratios of the relative risks associated with carvedilol for these two outcome variables in black as compared with nonblack patients were 0.74 (95 percent confidence interval, 0.42 to 1.34) and 0.94 (95 percent confidence interval, 0.43 to 2.05), respectively. Carvedilol also improved functional class, ejection fraction, and the patients' and physicians' global assessments in both the black patients and the nonblack patients. For all these measures of outcome and clinical status, carvedilol was superior to placebo within each racial cohort (P<0.05 in all analyses), and there was no significant interaction between race and treatment (P> 0.05 in all analyses). CONCLUSIONS: The benefit of carvedilol was apparent and of similar magnitude in both black and nonblack patients with heart failure. 相似文献
33.
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations
34.
A. Stathi J. Papaparaskevas L. Zachariadou A. Pangalis N. J. Legakis A. Tseleni-Kotsovili the Hellenic Strep-EURO Study Group P. T. Tassios 《Clinical microbiology and infection》2008,14(8):808-812
Among a total of 101 isolates from the first systematic multicentre surveillance effort concerning invasive Streptococcus pyogenes disease in Greece, conducted between 2003 and 2005 and covering 38% of the population, emm types 1 and 12 were prevalent, being responsible for 27 and nine cases, respectively. The isolates from the remaining 65 cases were assigned to 26 other emm types. Erythromycin resistance (12 isolates) was primarily mef (A)-mediated, although all emm type 1 strains were susceptible. Tetracycline resistance, due mostly to tet (M), was detected in 26 isolates. Subtyping by pulsed-field gel electrophoresis yielded 50 chromosomal fingerprints, thus discriminating further among ten of the 28 observed emm types. 相似文献
35.
36.
37.
Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients 总被引:4,自引:0,他引:4
Lichtenstein KA Delaney KM Armon C Ward DJ Moorman AC Wood KC Holmberg SD;HIV Outpatient Study Investigators 《Journal of acquired immune deficiency syndromes (1999)》2003,32(1):48-56
To identify clinical factors associated with the incidence of HIV-1-associated lipoatrophy, HIV-1-infected patients in the HIV Outpatient Study (HOPS) were prospectively evaluated for clinical signs of lipoatrophy at two visits about 21 months apart. Development of lipoatrophy was analyzed in stratified and multivariate analyses for its relationship to immunologic, virologic, clinical, and drug treatment information for each patient. Of 337 patients with no lipoatrophy at Survey 1, 44 (13.1%) developed moderate or severe lipoatrophy between the two surveys. In multivariate analyses, significant risk factors for incident lipoatrophy were white race (OR = 5.2; 95% CI: 1.9-17.1; =.003), CD4 T-lymphocyte count at Survey 2 less than 100 cells/mm3 (OR = 4.2; 95% CI: 1.3-13.1; =.013), and body mass index (BMI) less than 24 kg/m2 (OR = 2.4; 95% CI: 1.1-5.4; =.024). Analyses that controlled for the severity of HIV illness demonstrated no significant association with use of or time on any antiretroviral agent or class of agents and the development of lipoatrophy. Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy. 相似文献
38.
39.
40.